Company news
SELLAS Life Sciences Group, Inc. news in 2025
SELLAS Life Sciences Group, Inc.'s news releases, calls and decks from 2025, newest first.
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
December 29, 2025
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
December 7, 2025
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
November 3, 2025
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
October 27, 2025
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
October 22, 2025
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
October 13, 2025
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
September 30, 2025
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
September 11, 2025
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 12, 2025
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
August 7, 2025
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
July 15, 2025
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
July 6, 2025
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
June 24, 2025
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
June 5, 2025
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
June 2, 2025
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
May 20, 2025
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
May 15, 2025
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
April 28, 2025
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
April 8, 2025
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
March 20, 2025
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
February 20, 2025
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 27, 2025
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
January 22, 2025
SELLAS Announces Key Business Objectives for 2025
January 7, 2025
SELLAS to Host Corporate Update Call on January 8, 2025, at 9: 00 am ET
January 1, 2025